CLEVELAND, May 31, 2011 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focusedon global eClinical solutions for the clinical trials industry, today announced the Company's attendance at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held at McCormick Place in Chicago, IL
DATATRAK will be exhibiting on June 4th-6th in booth 19123. Individuals attending the meeting are encouraged to visit the booth to learn how DATATRAK's unified technology approach safely accelerates your oncology drug development time lines. DATATRAK will be demonstrating its oncology-specific solution, which utilizes the functions of the DATATRAK ONE™ unified suite of products. By building a suite of tools that share a common database, interface and point of access, a single process for your entire drug program from concept to cure™ can be implemented.
About ASCO Annual Meeting
The 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) will center around the theme of "Patients, Pathways, Progress." More than 30,000 cancer specialists from around the world will gather at the meeting to discuss the latest innovations in research, quality, practices and technology in cancer. For more information, please visit http://www.asco.org.
About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market announcing its results for the three-month period ending March 31, 2011. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
SOURCE DATATRAK International, Inc.
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All